Federal Register / Vol. 76, No. 161 / Friday, August 19, 2011 / Notices 51985 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per response (in hr) 

Tobacco Control Programs ............................. Quitline Promotion Activities Data ................. 50 4 10/60 

Intake Data for QL Clients ............................. 2 4 15/60 

Intake Data for Web Services Clients ............ 2 4 15/60 

Quitline Clients ................................................ Follow-up Survey for QL Clients .................... 2,000 1 15/60 

Web Services Clients ...................................... Follow-up Survey for Web Clients ................. 2,000 1 15/60 

Dated: August 15, 2011. 

Daniel Holcomb, 

Reports Clearance Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2011–21204 Filed 8–18–11; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Initial Review 

The meeting announced below 

concerns Special Interest Project (SIP): 

Systematic Review of Effective 

Community-based Interventions of 

Clinical Preventive Services for Older 

Adults, SIP11–045, initial review. 

Correction: This notice was published 

in the Federal Register on August 11, 

2011, Volume 76, Number 155, Page 

49771. The time for the aforementioned 

meeting has been changed to the 

following. 

Time 

12 p.m.–2 p.m., August 31, 2011 

(Closed). 

Contact Person for More Information: 

Robin Hamre, M.P.H., R.D., Scientific 

Review Officer, Extramural Research 

Program Office, National Center for 

Chronic Disease Prevention and Health 

Promotion, CDC, 4770 Buford Highway, 

NE., Mailstop K–92, Atlanta, Georgia 

30341, RWH9@cdc.gov. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Elizabeth Millington, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. 2011–21217 Filed 8–18–11; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

ICD–9–CM Coordination and 

Maintenance Committee Meeting 

National Center for Health Statistics 

(NCHS), Classifications and Public 

Health Data Standards Staff, announces 

the following meeting. 

Name: ICD–9–CM Coordination and 

Maintenance Committee meeting. 

Time and Date: 9 a.m.–5:30 p.m., 

September 14, 2011. 

Place: Centers for Medicare and 

Medicaid Services (CMS) Auditorium, 

7500 Security Boulevard, Baltimore, 

Maryland 21244. 

Status: Open to the public, limited 

only by the space available. The meeting 

room accommodates approximately 240 

people. 

Security Considerations: Due to 

increased security requirements CMS 

has instituted stringent procedures for 

entrance into the building by nongovernment employees. Attendees will 

need to present valid government-issued 

picture identification, and sign-in at the 

security desk upon entering the 

building. Attendees who wish to attend 

a specific ICD–9–CM C&M meeting on 

September 14, 2011, must submit their 

name and organization by September 9, 

2011, for inclusion on the visitor list. 

This visitor list will be maintained at 

the front desk of the CMS building and 

used by the guards to admit visitors to 

the meeting. 

Participants who attended previous 

ICD–9–CM C&M meetings will no longer 

be automatically added to the visitor 

list. You must request inclusion of your 

name prior to each meeting you attend. 

Please register to attend the meeting 

on-line at: http://www.cms.hhs.gov/ 

apps/events/. Please contact Mady Hue 

(410–786–4510 or 

Marilu.hue@cms.hhs.gov), for questions 

about the registration process. 

Purpose: The ICD–9–CM Coordination 

and Maintenance (C&M) Committee is a 

public forum for the presentation of 

proposed modifications to the 

International Classification of Diseases, 

Ninth-Revision, Clinical Modification. 

Matters To Be Discussed: Agenda 

items include: 

September 14, 2011 

ICD–10 Updates 

2012 ICD–10–PCS. 

2012 ICD–10–PCS GEM and 

Reimbursement Map Updates. 

ICD–10–PCS Official Coding 

Guidelines. 

ICD–10 MS–DRGs. 

ICD–9–CM Procedure Topics 

Electromagnetic Tip Tracked Sensor 

devices used in lung bronchoscopy and 

lung biopsy procedures. 

Extracorporeal Heart and Lung Assist 

System, including Membrane 

Oxygenation, CO2 Removal. 

ICD–10–PCS Topics 

Implantable meshes. 

ICD–10–CM Diagnosis Topics 

Aggressive periodontitis. 

Chronic Fatigue Syndrome. 

Chronic periodontitis. 

Gingival recession. 

Agenda items are subject to change as 

priorities dictate. 

Note: CMS and NCHS will no longer 

provide paper copies of handouts for the 

meeting. Electronic copies of all meeting 

materials will be posted on the CMS and 

NCHS websites prior to the meeting at http: 

//www.cms.hhs.gov/ 

ICD9ProviderDiagnosticCodes/ 

03_meetings.asp#TopOfPage and http:// 

www.cdc.gov/nchs/icd/ 

icd9cm_maintenance.htm. 

Contact Persons for Additional 

Information: Donna Pickett, Medical 

Systems Administrator, Classifications 

and Public Health Data Standards Staff, 

NCHS, 3311 Toledo Road, Room 2337, 

Hyattsville, Maryland 20782, e-mail 

dfp4@cdc.gov, telephone 301–458–4434 

(diagnosis); Mady Hue, Health 

Insurance Specialist, Division of Acute 

Care, CMS, 7500 Security Boulevard, 

Baltimore, Maryland 21244, e-mail 

marilu.hue@cms.hhs.gov, telephone 

410–786–4510 (procedures). 

The Director, Management Analysis 

and Services Office, has been delegated 


jlentini on DSK4TPTVN1PROD with NOTICES
51986 Federal Register / Vol. 76, No. 161 / Friday, August 19, 2011 / Notices 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention, and the Agency for Toxic 

Substances and Disease Registry. 

Dated: August 10, 2011. 

Elizabeth Millington, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. 2011–21167 Filed 8–18–11; 8:45 am] 

BILLING CODE 4160–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

President’s Committee for People With 

Intellectual Disabilities (PCPID); Notice 

of Meeting 

AGENCY: President’s Committee for 

People with Intellectual Disabilities 

(PCPID), Administration for Children 

and Families, HHS. 

ACTION: Notice of meeting. 

DATES: Monday, September 26, 2011, 

from 8:30 a.m. to 5 p.m. EST; and 

Tuesday, September 27, 2011, from 9 

a.m. to 5 p.m. EST. The meeting will be 

open to the public. 

ADDRESSES: The meeting will be held in 

Conference Room 505–A of the Hubert 

H. Humphrey Building, U.S. 

Department of Health and Human 

Services, 200 Independence Avenue, 

SW., Washington, DC 20201. 

Individuals who would like to 

participate via conference call may do 

so by dialing 800–857–4846, pass code: 

14201. Individuals who will need 

accommodations for a disability in order 

to attend the meeting (e.g., sign language 

interpreting services, assistive listening 

devices, materials in alternative format 

such as large print or Braille) should 

notify Genevieve Swift, PCPID 

Executive Administrative Assistant, via 

e-mail at Edith.Swift@acf.hhs.gov, or via 

telephone at 202–619–0634, no later 

than Monday, September 19, 2011. 

PCPID will attempt to meet requests for 

accommodations made after that date, 

but cannot guarantee ability to grant 

requests received after this deadline. All 

meeting sites are barrier free. 

Agenda: Committee members will 

discuss preparation of the PCPID 2011 

Report to the President, including its 

content and format, and related data 

collection and analysis required to 

complete the writing of the Report. 

Additional Information: For further 

information, please contact Laverdia 

Taylor Roach, Senior Advisor, 

President’s Committee for People with 

Intellectual Disabilities, The Aerospace 

Center, Second Floor West, 370 L’Enfant 

Promenade, SW., Washington, DC 

20447. Telephone: 202–619–0634. Fax: 

202–205–9519. E-mail: 

LRoach@acf.hhs.gov. 

SUPPLEMENTARY INFORMATION: PCPID 

acts in an advisory capacity to the 

President and the Secretary of Health 

and Human Services, through the 

Administration on Developmental 

Disabilities, on a broad range of topics 

relating to programs, services and 

supports for persons with intellectual 

disabilities. The PCPID Executive Order 

stipulates that the Committee shall: (1) 

Provide such advice concerning 

intellectual disabilities as the President 

or the Secretary of Health and Human 

Services may request; and (2) provide 

advice to the President concerning the 

following for people with intellectual 

disabilities: (A) Expansion of 

educational opportunities; (B) 

promotion of homeownership; (C) 

assurance of workplace integration; (D) 

improvement of transportation options; 

(E) expansion of full access to 

community living; and (F) increasing 

access to assistive and universally 

designed technologies. 

Dated: August 12, 2011. 

Jamie Kendall, 

Deputy Commissioner, Administration on 

Developmental Disabilities. 

[FR Doc. 2011–21240 Filed 8–18–11; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2011–N–0410] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Premarket 

Notification for a New Dietary 

Ingredient 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a proposed collection of 

information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995 

(the PRA). 

DATES: Fax written comments on the 

collection of information by September 

19, 2011. 

ADDRESSES: To ensure that comments on 

the information collection are received, 

OMB recommends that written 

comments be faxed to the Office of 

Information and Regulatory Affairs, 

OMB, Attn: FDA Desk Officer, FAX: 

202–395–7285, or e-mailed to 

oira_submission@omb.eop.gov. All 

comments should be identified with the 

OMB control number 0910–0330. Also 

include the FDA docket number found 

in brackets in the heading of this 

document. 

FOR FURTHER INFORMATION CONTACT: 

Denver Presley, Jr., Office of 

Information Management, Food and 

Drug Administration, 1350 Piccard Dr., 

PI50–400B, Rockville, MD 20850, 301– 

796–3793. 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. 

Premarket Notification for a New 

Dietary Ingredient—21 CFR 190.6— 

(OMB Control Number 0910–0330)— 

Extension 

Section 413(a) of the Federal Food, 

Drug, and Cosmetic Act (the FD&C Act) 

(21 U.S.C. 350b(a)) provides that at least 

75 days before the introduction or 

delivery for introduction into interstate 

commerce of a dietary supplement that 

contains a new dietary ingredient (NDI), 

a manufacturer or distributor of an NDI, 

or of the dietary supplement that 

contains the NDI, is to submit to FDA 

(as delegate for the Secretary of Health 

and Human Services) the information 

which is the basis on which the 

manufacturer or distributor has 

concluded that a dietary supplement 

containing an NDI will reasonably be 

expected to be safe. Section 190.6 (21 

CFR 190.6) implements this statutory 

provision. Section 190.6(a) requires 

each manufacturer or distributor of a 

dietary supplement containing an NDI, 

or of an NDI, to submit to the Office of 

Nutrition, Labeling, and Dietary 

Supplements notification of the basis for 

their conclusion that said supplement or 

ingredient will reasonably be expected 

to be safe. Section 190.6(b) requires that 

the notification include the following: 

(1) The complete name and address of 

the manufacturer or distributor, (2) the 

name of the NDI, (3) a description of the 

dietary supplements that contain the 

NDI, and (4) the history of use or other 

evidence of safety establishing that the 

dietary ingredient will reasonably be 

expected to be safe. 


jlentini on DSK4TPTVN1PROD with NOTICES